Cells (Mar 2022)

Phenotypical Screening on Neuronal Plasticity in Hippocampal-Prefrontal Cortex Connectivity Reveals an Antipsychotic with a Novel Profile

  • Michael Spedding,
  • Claude Sebban,
  • Thérèse M. Jay,
  • Cyril Rocher,
  • Brigitte Tesolin-Decros,
  • Paul Chazot,
  • Esther Schenker,
  • Gabor Szénási,
  • György I. Lévay,
  • Katalin Megyeri,
  • Jozsef Barkóczy,
  • Laszlo G. Hársing,
  • Ian Thomson,
  • Mark O. Cunningham,
  • Miles A. Whittington,
  • Lori-An Etherington,
  • Jeremy J. Lambert,
  • Ferenc A. Antoni,
  • Istvan Gacsályi

DOI
https://doi.org/10.3390/cells11071181
Journal volume & issue
Vol. 11, no. 7
p. 1181

Abstract

Read online

Dysfunction in the hippocampus-prefrontal cortex (H-PFC) circuit is a critical determinant of schizophrenia. Screening of pyridazinone-risperidone hybrids on this circuit revealed EGIS 11150 (S 36549). EGIS 11150 induced theta rhythm in hippocampal slice preparations in the stratum lacunosum molecular area of CA1, which was resistant to atropine and prazosin. EGIS 11150 enhanced H-PFC coherence, and increased the 8–9 Hz theta band of the EEG power spectrum (from 0.002 mg/kg i.p, at >30× lower doses than clozapine, and >100× for olanzapine, risperidone, or haloperidol). EGIS 11150 fully blocked the effects of phencyclidine (PCP) or ketamine on EEG. Inhibition of long-term potentiation (LTP) in H-PFC was blocked by platform stress, but was fully restored by EGIS 11150 (0.01 mg/kg i.p.), whereas clozapine (0.3 mg/kg ip) only partially restored LTP. EGIS 11150 has a unique electrophysiological profile, so phenotypical screening on H-PFC connectivity can reveal novel antipsychotics.

Keywords